ELMD

ElectromedA

NYSE American / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$42.00

Analysis reference price unavailable

Analysis 2026-08-28 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$34.00

Analysis reference price unavailable

Analysis 2026-08-28 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$23.00

Analysis reference price unavailable

Analysis 2026-08-28 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-28

AI commentary

Primary company evidence remains operationally strong, but the post-earnings narrative is mixed: record results and management’s long-term growth case were offset by hospital weakness, a slight reported revenue miss versus consensus, CEO succession risk, and a sharp decline to the August 27 anchor price of $30.14. Coverage is thin, social data and options data are unavailable, and analyst revisions are not established. The appropriate stance is cautious monitoring rather than a high-conviction bullish call.

RankAlpha Sentiment Codex - 2026-08-28

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-27eventMixed Q4/FY2026 print has triggered a post-earnings resetHigh impact

Electromed reported record Q4 revenue of $19.4 million, operating income of $3.8 million, diluted EPS of $0.39, and its 15th consecutive quarter of year-over-year revenue and profit growth. However, trusted post-print coverage reported a slight revenue miss versus consensus and a negative share reaction. The SEC filing also disclosed the planned CEO retirement.[#SEC-8K-2026-08-25]

2026-09-30catalystHospital-channel weakness and single-product concentration may continue to pressure sentimentHigh impact

Hospital revenue declined 29% in Q4, while management characterized hospital orders as longer-cycle and less predictable. ELMD remains a low-coverage, concentrated small-cap medtech issuer, so another weak hospital or prescription-conversion update could extend the recent repricing.

2027-04-02eventCEO succession becomes a defined execution checkpointMedium impact

CEO Jim Cunniff expects to retire on or about April 2, 2027, and the board has begun a national search with an executive search firm. The transition could be orderly, but the timing creates continuity and execution risk while the company is investing ahead of territory expansion.[#SEC-8K-2026-08-25]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-28 • Updated nightlySource: Internal modelMethodology